Prof. Dr. Asisa Volz
Universitätsprofessorin
direct dial
+49 511 953-8857
fax
+49 511 953-8898
![[Translate to English:] Univ. Prof. Dr. Asisa Volz](/fileadmin/21_Virologie/Bilder/personal/ProfVolz.jpg)
Publications
Ohrnberger, S., Meyer zu Natrup, C., Clever, S., Schünemann, L.-M., Armando, F., Ciurkiewicz, M., Baumgärtner, W., Kalodimou, G., Sutter, G., Tscherne, A., & Volz, A. (2025). Strong immunogenicity and protection against SARS-CoV-2 in hamsters induced by heterologous boost vaccination with an MVA-based COVID-19 vaccine candidate. The Journal of General Virology: JGV, 106(11), Article 2180. https://doi.org/10.1099/jgv.0.002180
read more
read more
Rosiak, M., Hülskötter, K., Gregor, K. M., Leitzen, E., Beythien, G., Clever, S., Ciurkiewicz, M., Allnoch, L., Meyer zu Natrup, C., Tuchel, T., Volz, A., & Baumgärtner, W. (2025). Quantitative evaluation of SARS-CoV-2 Infection associated lesions in the brains of K18-hACE2 mice. In Journal of comparative pathology (208). Elsevier BV. https://doi.org/10.1016/j.jcpa.2025.10.178
read more
read more
Rosiak, M., Schreiner, T., Beythien, G., Leitzen, E., Ulianytska, A., Allnoch, L., Becker, K., Michaely, L. M., Lockow, S., Clever, S., Meyer zu Natrup, C., Volz, A., Baumgärtner, W., Ciurkiewicz, M., Hülskötter, K., & Gregor, K. M. (2025). Spatiotemporal characterization of changes in the respiratory tract and the nervous system, including the eyes in SARS-CoV-2-infected K18-hACE2 mice. Viruses, 17(7), Article 963. https://doi.org/10.3390/v17070963
read more
read more
Seib, J., Meyer zu Natrup, C., Ohrnberger, S., Clever, S., & Asisa, V. (2025). Evaluation of innovative MVA-WNV candidate vaccines to overcome immunosenescence in old mice. In 18th Graduate School Day: 21 November 2025 : abstract book (Zoo P 11). Stiftung Tierärztliche Hochschule Hannover.
read more
read more
Tscherne, A., Kalodimou, G., Jany, S., Freudenstein, A., Kumar, S., Pilchová, V., Friebis, T., Maiwald, G., Panhofer, I., Sutter, G., & Volz, A. (2025). Robust polyfunctional CD8+ and CD4+ T cell responses in HLA-A* 0201/DR1 transgenic mice following vaccination with modified vaccinia virus Ankara-based vaccines delivering Lassa virus glycoprotein or nucleoprotein. The Journal of General Virology: JGV, 106(9), Article 2142. https://doi.org/10.1099/jgv.0.002142
read more
read more
Clever, S., Limpinsel, L., Meyer Zu Natrup, C., Schünemann, L.-M., Beythien, G., Rosiak, M., Hülskötter, K., Gregor, K. M., Tuchel, T., Kalodimou, G., Freudenstein, A., Kumar, S., Baumgärtner, W., Sutter, G., Tscherne, A., & Volz, A. (2024). Single MVA-SARS-2-ST/N vaccination rapidly protects K18-hACE2 mice against a lethal SARS-CoV-2 challenge infection. Viruses, 16(3), Article 417. https://doi.org/10.3390/v16030417
read more
read more
Clever, S., Schünemann, L.-M., Armando, F., Meyer Zu Natrup, C., Tuchel, T., Tscherne, A., Ciurkiewicz, M., Baumgärtner, W., Sutter, G., & Volz, A. (2024). Protective MVA-ST vaccination robustly activates T cells and antibodies in an aged-hamster model for COVID-19. Vaccines, 12(1), Article 52. https://doi.org/10.3390/vaccines12010052
read more
read more
Henneck, T., Mergani, A., Lynch-Miller, M., Volz, A., de Buhr, N., Mörgelin, M., & von Köckritz-Blickwede, M. (2024). SARS-CoV-2 induces vital NET formation independent of available oxygen. HypoxEU Live 2024, Dresden, 09.-12.06.2024.
read more
read more
Heydemann, L., Ciurkiewicz, M., Störk, T., Hülskötter, K., Gregor, K., Michaely, L., Reineking, W., Schreiner, T., Beythien, G., Volz, A., von Köckritz-Blickwede, M., Tuchel, T., Meyer zu Natrup, C., Schünemann, L.-M., Clever, S., Schaudien, D., Schughart, K., Geffers, R., Baumgärtner, W., & Armando, F. (2024). Sind Hamster ein geeignetes Modell für respiratorische, post-akute Folgen von SARS-CoV-2? In Tierärztliche Praxis / K (V04). Thieme. https://doi.org/10.1055/s-0044-1787313
read more
read more
Kumar, S., Nan, L., Kalodimou, G., Jany, S., Freudenstein, A., Brandmüller, C., Müller, K., Girl, P., Ehmann, R., Guggemos, W., Seilmaier, M., Wendtner, C.-M., Volz, A., Sutter, G., Fux, R., & Tscherne, A. (2024). Implementation of an immunoassay based on the MVA-T7pol-expression system for rapid identification of immunogenic SARS-CoV-2 antigens: a proof-of-concept study. International Journal of Molecular Sciences, 25(20), Article 10898. https://doi.org/10.3390/ijms252010898
read more
read more
further Publications
2020
- Trick-Borne Encephalitis Virus: A Quest for Better Vaccines against a Virus on the Rise. (pdf, 1,45 MB)
Kubinski M., Beicht J., Gerlach T., Volz A., Sutter G., Rimmelzwaan G.F.
Vaccines (Basel). 2020;8(3):E451. Published 2020 Aug 12. doi:10.3390/vaccines8030451
2018
- CD8+ T cells responding to the Middle East respiratory syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. (pdf, 2,035 KB)
Veit S., Jany S., Fux R., Sutter G., Volz A.
Viruses 2018, 10(12), 718; doi:103390/v10120718 - Generation of therapeutic antisera for emerging viral infections. (pdf, 1,600 KB)
Schmidt R., Beltzig L.C., Sawatsky B., Dolnik O., Dietzel E., Krähling V., Volz A., Suter G., Becker S, von Messling V.
NPJ Vaccines, 2018 Oct 5, 3:42, doi:10.1038/s41541-0018-0082-4, eCollection - Immunogenic cell death of dendritic cells following modified vaccinia virus Ankara infection enhances CD8+ T cell proliferation. (pdf, 1,750 KB)
Tappe K.A., Budida R., Stankov M.V., Frenz T., Shah H., Volz A., Sutter G., Kalinke U., Behrens G.M.N.
Eur. J. Immunol., 48(12), 2042-2054 (2018) - Tracking Modified Vaccinia Virus Ankara in the Chicken Embryo: In Vivo Tropism and Pathogenesis of Egg Infections. (pdf, 1,755 KB)
Langenmayer M., Lülf-Averhoff A-T, Adam-Neumair S., Sutter G., Volz A.
Viruses, 10(9), pii: E452 (2018), doi:10.3390/ v10090452 - Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. (pdf, 1,39 MB)
Langenmayer M.C., Lülf-Averhoff A.T., Adam-Neumair S., Fux R., Sutter G., Volz A.
Biologicals, 54, 58-62 (2018) - E3L and F1L gene functions modulate the protective capacity of modified vaccinia virus Ankara immunization in murine model of human smallpox. (pdf, 1,221 KB)
Volz A., Jany S., Freudenstein A., Lantermann M., Ludwig H., Sutter G.,
Viruses, 10(1), 21 (2018)
2017
- Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo. (pdf, 8,35 MB)
Altenburg A.F., Sandt C.E. van de, Li B.W.S., MacLoughlin R.J., Fouchier R.A.M., Amerongen G. van, Volz A., Hendriks R.W., Swart R.L. de, Sutter G., Rimmelzwaan G.F., Vries R.D. de.
Sci. Rep., 7(1), Art. Nr. 8580 (2017). doi:10.1038/s41598-017-08719-y - A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells. (pdf, 1,89 MB)
Link E.K., Brandmüller C., Suezer Y., Ameres S., Volz A., Moosmann A., Sutter G., Lehmann M.H.
Vaccine, 35(38), 5131-5139 (2017) - Modified Vaccinia virus Ankara: History, value in basic research, and current perspectives for vaccine development. (pdf, 11 MB)
Volz A., Sutter G.
Advances in Virus Res., 97,187-243 (2017)
2016
- Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes. (pdf, 843 KB)
Lülf A.T., Freudenstein A., Marr L., Sutter G., Volz A.
Virology, 499, 322-330 (2016) - Increased protein degradation improves influenza Virus nucleoprotein-specific CD8+ T cell activation in vitro but not in C57BL/6 mice. (pdf, 1,83 MB)
Altenburg A.F., Sandt C.E. van de, Trierum S.E. van, Gruyter H.L. De, Run P.R. van, Fouchier R.A., Roose K., Saelens X., Volz A., Sutter G., Vries R.D. de,
Rimmelzwaan G.F.
J. Virol., 90(22), 10209-10219 (2016) - Low pathogenic avian influenza (H9N2) in chicken: Evaluation of an ancestral H9-MVA vaccine. (pdf, 1,03 MB)
Ducatez M., Becker J., Freudenstein A., Delverdier M., Delpont M., Sutter G., Guerin J.-L., Volz A.
Vet. Microbiol., 189, 59-67 (2016) - Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens.
(pdf, 1,75 MB)
Volz A., Lim S., Kaserer M., Lülf A., Marr L., Jany S., Deeg C.A., Pijlman G.P.,
Koraka P., Osterhaus A.D., Martina B.E., Sutter G.
Vaccine, 34(16), 1915-1926 (2016) - Myristoylation increases the CD8+ T cell response to a GFP prototype antigen delivered by modified vaccinia virus Ankara. (pdf, 1,05 MB)
Marr L., Lülf A.T., Freundenstein A., Sutter G., Volz A.
J. Gen. Virol., 97(4), 934-940 (2016) - An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. (pdf, 12,3 MB)
Haagmans B.L., Brand J.M.A. van den, Raj S.V., Volz A., Wohlsein P., Smits S.L., Schipper D., Bestebroer T.M., Okba N., Fux R., Bensaid A., Solanes Foz D.S., Kuiken T., Baumgärtner W., Segales J., Sutter G., Osterhaus A.D.M.E.
Science, 351(6268), 77-81 (2016)
2015
- Modifiziertes Vacciniavirus Ankara (MVA) - die Entwicklung als Vektorimpfstoff und Einsatzmöglichkeiten in der Veterinärmedizin. (pdf, 1,43 MB)
Volz A., Fux R., Langenmayer M.C., Sutter G.
Berl. Münch. Tierärztl. Wochenschr., 128(11/12), 464-472 (2015) - Protective efficacy of recombinant Modified Vaccinia vurus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. (pdf, 1,84 MB)
Volz A., Kupke A., Song F., Jany S., Fux R., Shams-Eldin H., Schmidt J., Becker C., Eickmann M., Becker S., Sutter G.
J. Virol., 89(19), 8651-8656 (2015)
2014
-
Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influeza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial. (pdf, 276 KB)
Kreijtz J.H.C.M., Goeijenbier M., Moesker F.M., Dries L. van den, Goeijenbier S., Gruyter H.L.M. De, Lehmann M.H., Mutsert G. de, Vijver D.A.M.C. van de, Volz A., Fouchier R.A.M., Gorp E.C.M. van, Rimmelzwaan G.F., Sutter G., Osterhaus A.D.M.E.
Lancet Infect. Dis., 14(12), 1196-1207 (2014) - Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge. (1,71 MB)
Doel P. van den, Volz A., Roose J.M., Sewbalaksing V.D., Pijlman G.P., Middelkoop I. van, Duiverman V., Wetering E. van de, Sutter G., Osterhaus A.D.M.E.,
Byron M.E.E.
PLOS Neglected Tropical Diseases, 8(9), e3101 (2014) - Modified vaccinia virus Ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. (pdf, 817 KB)
Altenburg A.F., Kreijtz J.H.C.M., Vries R.D. de, Song F., Fux R., Rimmelzwaan G.F., Sutter G., Volz A.
Viruses, 6(7), 2735-2761 (2014) - Rapit expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara. (5,22 MB)
Volz A., Langenmayer M., Jany S., Kalinke U., Sutter G.
J. Virol., 88(18), 10946-10957 (2014)
2013
- Middle east respiratory syndrome Coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.
(pdf, 155 KB)
Song F., Fux R., Provacia L.B., Volz A., Eickmann M., Becker S., Osterhaus A.D.M.E., Haagmans B.L., Sutter G.
J. Virol., 87(21), 11950-11954 (2013) - Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies.
(pdf, 269 KB)
Volz A., Sutter G.
Vaccine, 31(39), 4235-4240 (2013)
2012
- Easy and efficient protocols for working with recombinant vaccinia virus MVA.
(online-abstract)
Kremer M., Volz A., Kreijtz J.H., Fux R., Lehmann M.H., Sutter G.
Methods Mol. Biol., 890, 59-92 (2012) - Critical role of perforin-dependent CD8+ T cell immunity for rapid protective vaccination in a murine model for human smallpox. (pdf, 2,1 MB)
Kremer M.*, Suezer Y.*, Volz A.*, Frenz T., Majzoub M., Hanschmann K.-M., Lehmann M.H., Kalinke U., Sutter G.
PLoS Pathogens, 8(3), e1002557 (2012); *equal contribution
2011
- N1L is an ectromelia virus virulence factor and essential for in vivo spread upon respiratory infection. (pdf, 3,1 MB)
Gratz M. S., Suezer Y., Kremer M., Volz A., Majzoub M., Hanschmann K.-M., Kalinke U., Schwantes A., Sutter G.
J. Virol., 85(7), 3557-3569 (2011)
